Merck

516535

Sigma-Aldrich

PERK Inhibitor I, GSK2606414

GSK2606414 is a cell-permeable, highly potent inhibitor of EIF2AK3/PERK (IC₅₀ = 0.4 nM; [ATP] = 5 µM). Targets PERK in its inactive DFG conformation at the ATP-binding region.

ログイン組織・契約価格を表示する

別名:
PERK Inhibitor I, GSK2606414
実験式(ヒル表記法):
C24H20F3N5O
CAS番号:
分子量:
451.44
MDL番号:

品質水準

アッセイ

≥99% (HPLC)

形状

powder

メーカー/製品名

Calbiochem®

保管条件

OK to freeze
protect from light

white

溶解性

DMSO: 100 mg/mL

輸送温度

ambient

保管温度

−20°C

SMILES記法

O=C(CC1=CC=CC(C(F)(F)F)=C1)N2CCC3=C2C=CC(C4=CN(C)C5=C4C(N)=NC=N5)=C3

InChI

1S/C24H19F4N5O/c1-32-11-18(21-22(29)30-12-31-23(21)32)14-2-3-19-15(9-14)4-5-33(19)20(34)8-13-6-16(24(26,27)28)10-17(25)7-13/h2-3,6-7,9-12H,4-5,8H2,1H3,(H2,29,30,31)

InChI Key

PXVQGBJMIQCDEX-UHFFFAOYSA-N

類似した製品をお探しですか? Visit 製品比較ガイド

類似品目との比較

比較内容をすべて表示

相違点を表示

1 of 4

当該品目
218719528245328007
PERK Inhibitor I, GSK2606414 GSK2606414 is a cell-permeable, highly potent inhibitor of EIF2AK3/PERK (IC₅₀ = 0.4 nM; [ATP] = 5 µM). Targets PERK in its inactive DFG conformation at the ATP-binding region.

516535

PERK Inhibitor I, GSK2606414

PLD Inhibitor, FIPI The PLD Inhibitor, FIPI controls the biological activity of PLD. This small molecule/inhibitor is primarily used for Membrane applications.

528245

PLD Inhibitor, FIPI

ERK Inhibitor II, FR180204 ERK Inhibitor II, FR 180204, CAS 865362-74-9, is a cell-permeable, potent, ATP-competitive inhibitor of ERK1 and ERK2 (IC₅₀ = 510 nM and 330 nM; Ki = 310 nM and 140 nM, respectively).

328007

ERK Inhibitor II, FR180204

form

powder

form

solid

form

powder

form

solid

Quality Level

200

Quality Level

100

Quality Level

100

Quality Level

100

manufacturer/tradename

Calbiochem®

manufacturer/tradename

Calbiochem®

manufacturer/tradename

Calbiochem®

manufacturer/tradename

Calbiochem®

storage temp.

−20°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

solubility

DMSO: 100 mg/mL

solubility

DMSO: 50 mg/mL

solubility

DMSO: 100 mg/mL

solubility

DMSO: 10 mg/mL

詳細

A cell-permeable pyrrolopyrimidamine compound that acts as a highly potent EIF2AK3/PERK inhibitor (IC50 = 0.4 nM; [ATP] = 5 µM) by targeting PERK in its inactive DFG conformation at the ATP-binding region, while displaying ≥385-fold selectivity over c-Kit, Aurora B, BRK, HRI/EIF2AK1, MLK2/MAP3K10, c-MER, DDR2, PKR/EIF2AK2, and MLCK2/MYLK2 (IC50 = 154, 407, 412, 420, 452, 474, 524, 696, and 701 nM, respectively) and little activity against more than 280 other kinases (IC50 >1 µM). Shown to block ER stress-induced PERK autophosphorylation following Thapsigargin (Cat. No. 586005) addition in A549 cultures in vitro (by 100% at ≤30 nM; 60 min preincubation) and effectively retard PxBC-3 tumor growth in mice in vivo (50 and 150 mg/kg/12 h p.o.). Also available as a 25 mM solution in DMSO (Cat. No. 508340).
A cell-permeable pyrrolopyrimidinamine compound that acts as a highly potent inhibitor against EIF2AK3/PERK-catalyzed EIF2α Ser51 phosphorylation in kinase assays (IC50 = 0.4 nM; 30 min preincubation; [ATP] = 5 µM) as well as ER stress-induced PERK autophosphorylation following Thapsigargin (Cat. No. 586005) addition in A549 cultures (by 100% with ≤30 nM inhibitor; 60 min preincubation) by targeting PERK in its inactive conformation at the ATP-binding region. Displays ≥385-fold selectivity over c-Kit, Aurora B, BRK, HRI/EIF2AK1, MLK2/MAP3K10, c-MER, DDR2, PKR/EIF2AK2, and MLCK2/MYLK2 (IC50 = 154, 407, 412, 420, 452, 474, 524, 696, and 701 nM, respectively) and exhibits much reduced or little activity against more than 280 other kinases (IC50 >1 µM). Reported to be orally available in dog, mouse, and rat with good pharmacokinetics and retard the growth of established PxBC-3 tumor mass in mice in vivo (by 20% and 59% at the end of a 21 day treatment period with b.i.d. oral dosage of 50 and 150 mg/kg, respectively). The preincubation time-dependent inhibition, extremely slow dissociation rate, as well as the observed PERK selectivity, are all consistent with the inhibitor targeting PERK in its inactive DFG conformation.

生物化学的/生理学的作用

Cell permeable: yes
Primary Target
Perk
Reversible: yes
Target IC50: 0.4 nM against EIF2AK3/PERK-catalyzed EIF2&alpha

包装

Packaged under inert gas

警告

Toxicity: Standard Handling (A)

再構成

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

法的情報

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

保管分類コード

11 - Combustible Solids

WGK

WGK 3

引火点(°F)

Not applicable

引火点(℃)

Not applicable


試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

過去にご購入いただいた製品に関する文書は、文書ライブラリにまとめられています。是非ご利用ください。

文書ライブラリにアクセスする

製品・ロット/バッチ番号の検索

ウェブサイトの表示では、製品番号に容量/数量が連結しています(例:T1503-25G)。確認してください 製品番号欄には製品番号のみを入力してください (: T1503).

T1503
製品番号
-
25G
容量/数量

その他の例:

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

以下のように入力してください 1.000309185)

ご不明な点がございましたら、お気軽にお問い合わせくださいテクニカルサービス お問い合わせ

ロット番号とバッチ番号は、製品ラベルで「Lot」または「Batch」の言葉に続いて記載されています。

Aldrich製品

  • もしTO09019TOなどのロット番号を見つけた場合は、最初の2文字を除いたロット番号09019TOを入力します。

  • もし05427ES-021などの充てんコード付きロット番号を見つけた場合は、充てんコードの-021を除いたロット番号05427ESを入力します。

  • もしSTBB0728K9などの充てんコード付きロット番号を見つけた場合は、充てんコードのK9を除いたロット番号STBB0728を入力します。

お探しのものが見つかりませんか?

オンラインでCOAを入手できない場合があります。検索してもCOAが見つからない場合は、リクエストできます。

COAをリクエストする

この製品を見ている人はこちらもチェック

Slide 1 of 8

1 of 8

PKR Inhibitor The PKR Inhibitor, also referenced under CAS 608512-97-6, controls the biological activity of PKR. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

Sigma-Aldrich

527450

PKR Inhibitor

Sigma-Aldrich

Sigma-Aldrich

SML0951

サルブリナール

GSK2850163 ≥98% (HPLC)

Sigma-Aldrich

SML1684

GSK2850163

ISR Inhibitor, ISRIB

Sigma-Aldrich

5.09584

ISR Inhibitor, ISRIB

GSK621 ≥98% (HPLC)

Sigma-Aldrich

SML2003

GSK621

トヨカマイシン ≥98% (HPLC), from Streptomyces rimosus

Sigma-Aldrich

T3580

トヨカマイシン

Liliana Matos et al.
The journals of gerontology. Series A, Biological sciences and medical sciences, 70(8), 924-935 (2014-08-26)
The aging process is characterized by progressive accumulation of damaged biomolecules in the endoplasmic reticulum, as result of increased oxidative stress accompanying cellular senescence. In agreement, we hypothesized that WI-38 human cellular models of replicative senescence and stress-induced premature senescence
Bibha Dahal et al.
Virology, 539, 121-128 (2019-11-17)
Venezuelan equine encephalitis virus (VEEV) is a neurotropic virus that causes significant disease in both humans and equines. Here we characterized the impact of VEEV on signaling pathways regulating cell death in human primary astrocytes. VEEV productively infected primary astrocytes
Daniel R Sandoval et al.
bioRxiv : the preprint server for biology (2021-04-02)
We identify the prolyl-tRNA synthetase (PRS) inhibitor halofuginone 1 , a compound in clinical trials for anti-fibrotic and anti-inflammatory applications 2 , as a potent inhibitor of SARS-CoV-2 infection and replication. The interaction of SARS-CoV-2 spike protein with cell surface
Kai Chen et al.
Aging cell, 21(4), e13592-e13592 (2022-03-18)
Delirium is the most common postoperative complication in older patients after prolonged anesthesia and surgery and is associated with accelerated cognitive decline and dementia. The neuronal pathogenesis of postoperative delirium is largely unknown. The unfolded protein response (UPR) is an
Maria Saveria Gilardini Montani et al.
British journal of cancer, 123(2), 298-306 (2020-05-19)
Kaposi's Sarcoma Herpesvirus (KSHV) is a gammaherpesvirus strongly linked to human cancer. The virus is also able to induce immune suppression, effect that contributes to onset/progression of the viral-associated malignancies. As KSHV may infect macrophages and these cells abundantly infiltrate

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

テクニカルサービス連絡先